Treatment of lysosomal storage disorders: successes and challenges
- 13 May 2014
- journal article
- research article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 37 (4), 587-598
- https://doi.org/10.1007/s10545-014-9718-3
Abstract
Treatment options for a number of lysosomal storage disorders have rapidly expanded and currently include enzyme replacement therapy, substrate reduction, chaperone treatment, hematopoietic stem cell transplantation, and gene-therapy. Combination treatments are also explored. Most therapies are not curative but change the phenotypic expression of the disease. The effectiveness of treatment varies considerably between the different diseases, but also between sub-groups of patients with a specific lysosomal storage disorder. The heterogeneity of the patient populations complicates the prediction of benefits of therapy, specifically in patients with milder disease manifestations. In addition, there is a lack of data on the natural history of diseases and disease phenotypes. Initial trial data show benefits on relevant short-term endpoints, but the real world situation may reveal different outcomes. Collaborative international studies are much needed to study the long-term clinical efficacy of treatments, and to detect new complications or associated conditions of the diseases. This review summarizes the available treatment modalities for lysosomal storage disorders and the challenges associated with long term clinical care for these patients.This publication has 104 references indexed in Scilit:
- Spinal involvement in mucopolysaccharidosis IVA (Morquio‐Brailsford or Morquio A syndrome): presentation, diagnosis and managementJournal of Inherited Metabolic Disease, 2013
- Anaesthesia and airway management in mucopolysaccharidosisJournal of Inherited Metabolic Disease, 2012
- Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblastsProceedings of the National Academy of Sciences of the United States of America, 2011
- Hsp70 stabilizes lysosomes and reverts Niemann–Pick disease-associated lysosomal pathologyNature, 2010
- The Pharmacological Chaperone 1-Deoxygalactonojirimycin Reduces Tissue Globotriaosylceramide Levels in a Mouse Model of Fabry DiseaseMolecular Therapy, 2010
- Use of a Modified α-N-Acetylgalactosaminidase in the Development of Enzyme Replacement Therapy for Fabry DiseaseAmerican Journal of Human Genetics, 2009
- The Pharmacological Chaperone N-butyldeoxynojirimycin Enhances Enzyme Replacement Therapy in Pompe Disease FibroblastsMolecular Therapy, 2009
- Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1 −/− mouseProceedings of the National Academy of Sciences of the United States of America, 2009
- Randomized, controlled trial of miglustat in Gaucher's disease type 3Annals of Neurology, 2008
- Elevated globotriaosylsphingosine is a hallmark of Fabry diseaseProceedings of the National Academy of Sciences of the United States of America, 2008